We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Public AEDs Double Survival of Cardiac Arrest Patients

By HospiMedica staff writers
Posted on 01 Sep 2004
A large multicity study has found that deploying automatic external defibrillators (AEDs) in public places and training people how to use them can double the chance that victims of sudden cardiac arrest (SCA) will survive. More...


Currently, 95% of SCA victims die before reaching the hospital, due to the length of time it takes for emergency medical personnel to arrive on the scene. The chance of survival is reduced by 10% for every minute spent waiting for a life-saving defibrillation shock.

About 20,000 volunteers took part in the study, in which half were taught to use AEDs and perform cardiopulmonary resuscitation (CPR) and the balance to perform only CPR. Around 1,500 automated defibrillators were placed in more than 990 public facilities, including office buildings, factories, airports, shopping centers, and sports venues in 24 cities. During the two-year study, 124 cardiac arrests occurred in public facilities where an AED was available, and 31% of those people survived vs only 17% of the 86 arrests that occurred in venues where only conventional responses, CPR and a call to 911, were available. The results of the study showed almost a two-fold chance of surviving SCA after use of an AED, confirming the benefits found in a small, earlier study.

The study was conducted by the U.S. National Heart, Lung and Blood Institute (NHLBI) and the American Heart Association (AMA). The AED devices were provided by Cardiac Science (Irvine, CA, USA), and the study results were reported in the August 12, 2004, issue of the New England Journal of Medicine.




Related Links:
U.S. National Heart, Lung and Blood Institute
American Heart Association

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.